会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • Selective s1p1/edg1 receptor agonists
    • 选择性s1p1 / edg1受体激动剂
    • US20050070506A1
    • 2005-03-31
    • US10501176
    • 2003-01-14
    • George DohertyMichael ForrestRichard HajduJeffrey HaleLi ZhenSusanne MandalaSander MillsHugh RosenEdward Scolnick
    • George DohertyMichael ForrestRichard HajduJeffrey HaleLi ZhenSusanne MandalaSander MillsHugh RosenEdward Scolnick
    • A61K31/00A61K31/66G01N33/566
    • A61K31/66A61K31/00G01N33/566G01N2500/04
    • The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor, said compound administered in an amount effective for treating said immunoregulatory abnormality. Pharmaceutical compositions are included. The invention also encompasses a method of identifying candidate compounds that are agonists of the S1P1/Edg1 receptor and which possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor. The invention further encompasses a method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said respiratory disease or condition, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor.
    • 本发明包括在需要这种治疗的哺乳动物患者中治疗免疫调节异常的方法,包括以有效治疗所述免疫调节异常的量向所述患者施用作为S1P1 / Edg1受体激动剂的化合物,其中所述化合物 对S1P1 / Edg1受体具有S1PR3 / Edg1受体的选择性,所述化合物以有效治疗所述免疫调节异常的量给药。 包括药物组合物。 本发明还包括鉴定作为S1P1 / Edg1受体的激动剂的候选化合物的方法,并且其具有S1P1 / Edg1受体超过S1PR3 / Edg3受体的选择性。 本发明还包括治疗需要这种治疗的哺乳动物患者的呼吸系统疾病或病症的方法,包括向所述患者施用有效治疗所述呼吸系统疾病或病症的S1P1 / Edg1受体激动剂的化合物 其中所述化合物对S1P1 / Edg1受体具有超过S1PR3 / Edg3受体的选择性。